Not Signed In -
Imipenem and Cilastatin Sodium Injection |
Primaxin |
Clinical Trial: Follow-Up Study of Safety of Enteric-Coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
This study is no longer recruiting patients.
|
Purpose
Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate sodium in regard to adverse events, serious adverse events and patient and graft survival. After successful completion of the study CERL080A0107 study, patients could continue to receive enteric-coated mycophenolate sodium.
| Condition | Intervention | Phase |
|---|---|---|
| Renal transplant | Drug: Mycophenolate sodium (enteric coated) | Phase III |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: Multicenter, Open-Label Follow-Up Study on the Safety of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients.
Further Study Details:
Study start: March 2000
Eligibility
Ages Eligible for Study: 18 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Cadaveric or living donor kidney transplant recipients who completed the study CERL080A0107
Exclusion Criteria:
- Other protocol-defined inclusion/exclusion criteria may apply.
Location Information
Study chairs or principal investigators
Novartis, Study Director, Novartis
More Information
Study ID Numbers: CERL080A107E
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00149916
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00149916
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
